Figure 5
Figure 5. INCB018424 does not affect normal hematologic parameters. Mice (n = 5/group) were treated with INCB018424 or vehicle for 4 weeks at a total daily dose of 180 mg/kg (A). Data are reported for total white blood cell counts (WBC, 103/μL), absolute neutrophil counts (ANEU, 103/μL), absolute lymphocyte counts (ALYM, 103/μL), red blood cells (RBC, 106/μL), reticulocytes (RET, 103/μL), and platelets (PLT, 103/μL). No significant differences were found between treatment groups. For comparison, a subset of parameters was measured in mice treated with cyclophosphamide for 2 weeks (CTX, B). All parameters were significantly decreased by CTX (P < .01). Statistical significance was determined using Dunnett test.

INCB018424 does not affect normal hematologic parameters. Mice (n = 5/group) were treated with INCB018424 or vehicle for 4 weeks at a total daily dose of 180 mg/kg (A). Data are reported for total white blood cell counts (WBC, 103/μL), absolute neutrophil counts (ANEU, 103/μL), absolute lymphocyte counts (ALYM, 103/μL), red blood cells (RBC, 106/μL), reticulocytes (RET, 103/μL), and platelets (PLT, 103/μL). No significant differences were found between treatment groups. For comparison, a subset of parameters was measured in mice treated with cyclophosphamide for 2 weeks (CTX, B). All parameters were significantly decreased by CTX (P < .01). Statistical significance was determined using Dunnett test.

Close Modal

or Create an Account

Close Modal
Close Modal